Literature DB >> 15138876

Antierythropoietin antibody-induced pure red cell aplasia: posttransplant evolution.

Angel Alonso Melgar1, Marta Melgosa Hijosa, Rafael Pardo de la Vega, Carmen García Meseguer, Mercedes Navarro Torres.   

Abstract

Pure red cell aplasia is a rare complication of recombinant human erythropoietin (rHuEPO) treatment, which physicians should consider once the more frequent causes of hyporegenerative anemia have been excluded. To our knowledge, no pediatric cases have been described. In our patient, cyclosporin A treatment enabled a reduction in the number of transfusions and the risk of hyperimmunization. After transplantation, our patient's hemoglobin level has remained normal and stable.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15138876     DOI: 10.1007/s00467-004-1489-x

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  10 in total

1.  Successful treatment of pure red cell aplasia associated with systemic lupus erythematosus with cyclosporin A.

Authors:  C Duarte-Salazar; J Cazarín-Barrientos; M V Goycochea-Robles; J Collazo-Jaloma; R Burgos-Vargas
Journal:  Rheumatology (Oxford)       Date:  2000-10       Impact factor: 7.580

2.  Drug-induced autoimmune red-cell aplasia.

Authors:  H Franklin Bunn
Journal:  N Engl J Med       Date:  2002-02-14       Impact factor: 91.245

3.  Pure red-cell aplasia due to anti-erythropoietin antibodies.

Authors:  Kai-Uwe Eckardt; Nicole Casadevall
Journal:  Nephrol Dial Transplant       Date:  2003-05       Impact factor: 5.992

4.  Antibodies to recombinant human erythropoietin causing pure red cell aplasia.

Authors:  S S Prabhakar; T Muhlfelder
Journal:  Clin Nephrol       Date:  1997-05       Impact factor: 0.975

Review 5.  Pure red-cell aplasia.

Authors:  S B Krantz
Journal:  N Engl J Med       Date:  1974-08-15       Impact factor: 91.245

6.  Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia.

Authors:  R Peces; M de la Torre; R Alcázar; J M Urra
Journal:  N Engl J Med       Date:  1996-08-15       Impact factor: 91.245

7.  Cyclosporine treatment for patients with CRF who developed pure red blood cell aplasia following EPO therapy.

Authors:  Wee J Chng; Lip K Tan; Te C Liu
Journal:  Am J Kidney Dis       Date:  2003-03       Impact factor: 8.860

8.  [Pure red blood cell aplasia associated with neutralizing antibodies against erythropoietin induced by epoetin alfa:a new form of acquired erythroblastopenia in auremic patients].

Authors:  A Cases; N Esforzado; M Mas; M J Ricart; J M Cruzado
Journal:  Nefrologia       Date:  2003       Impact factor: 2.033

9.  Erythrocyte aplasia and systemic lupus erythematosus.

Authors:  P D Kiely; C P McGuckin; D A Collins; D H Bevan; J C Marsh
Journal:  Lupus       Date:  1995-10       Impact factor: 2.911

10.  Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins.

Authors:  Gertrud Weber; Johann Gross; Arno Kromminga; Hans-H Loew; Kai-Uwe Eckardt
Journal:  J Am Soc Nephrol       Date:  2002-09       Impact factor: 10.121

  10 in total
  2 in total

1.  Anti-erythropoietin antibodies followed by endogenous erythropoietin production in a dialysis patient.

Authors:  Parnell Mattison; Kiran Upadhyay; Jennifer E Wilcox; Asha Moudgil; Douglas M Silverstein
Journal:  Pediatr Nephrol       Date:  2010-01-21       Impact factor: 3.714

2.  A 46-Year-Old Thai Woman with Secondary Acquired Pure Red Cell Aplasia Due to Treatment with Recombinant Erythropoietin While on Dialysis for End-Stage Renal Disease Who Recovered Following ABO-Incompatible Kidney Transplantation.

Authors:  Rungthiwa Kitpermkiat; Sansanee Thotsiri; Nuttaporn Arpornsujaritkun; Premsant Sangkum; Pichika Chantrathammachart; Pimpun Kitpoka; Duangtawan Thammanichanond; Tanist Virankabutra; Surasak Kantachuvesiri
Journal:  Am J Case Rep       Date:  2022-07-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.